NASDAQ$AKYA

Akoya Biosciences Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Briefing

Akoya reported record revenue and the milestone of the 1,000th publication featuring Akoya platforms in the second quarter of 2023.

Akoya Biosciences reported a strong financial performance in Q2 2023, achieving record revenue of $23.5 million, a 31% increase year-over-year. The company highlighted its leading position in spatial biology and its focus on moving towards profitability.

  • Total revenue reached $23.5 million, a 31% increase compared to the prior year period.
  • Product revenue (instruments, reagents, and software) increased by 20% to $17.1 million.
  • Service and other revenue grew significantly by 73% to $6.4 million.
  • Gross profit was $12.1 million with a gross profit margin of 51.5%.

Headline financials

Total Revenue

$23.5M

Previous: $17.9M+31.4%
EPS (adj)

-$0.51

Previous: -$0.47-8.5%
Capital Expenditures

$1.42M

Previous: $1.56M-9.0%
Free Cash Flow

-$13.2M

Previous: -$15M+11.5%
Net Income

-$20.8M

Previous: -$17.5M-18.9%
Operating Income

-$19.2M

Previous: -$17.5M-10.2%
Gross Profit

$12.1M

Previous: $10.3M+17.2%
Cash & Equivalents

$93.3M

Previous: $46.9M+99.1%
Total Assets

$189M

Previous: $184M+2.5%
Stock-Based Comp

$2.62M

Previous: $1.72M+52.2%

Revenue & EPS history

Akoya · Revenue · Quarterly

$23.5M

Q2 2023+31.4%vs Q2 2022
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

Akoya · $23.5M total across 2 segments · Q2 2023

  • Product revenue
    $17.1M+21.1%
  • Service and other revenue
    $6.37M+70.7%

Forward guidance

The company continues to expect full year 2023 revenue in the range of $95-98 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 10 quarterly earnings reports · overlaid with Q2 2023

Historical avgQ2 2023

-3.7%

Avg return

Earnings day

-8.6%

Avg return

5 days after

-17.2%

Avg return

30 days after

53%

10 / 19 earnings

Positive

+13.7%

Q4 2021

Best reaction

-31.9%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025
Q1 2025+1.0%+24.8%+23.8%
Q4 2025+3.8%+9.2%-30.7%
Q3 2024-24.9%-33.2%-29.5%
Q2 2024-9.5%-0.9%+5.5%
Q1 2024-31.9%-35.1%-50.0%
Q4 2023-15.4%-17.1%-28.1%
Q3 2023+10.0%+6.9%+16.4%
Q2 2023+0.9%-6.5%-23.9%
Q1 2023-2.5%-17.1%-18.8%
Q4 2022-7.3%-17.2%-36.6%
Q3 2022-15.1%
Q2 2022+5.0%
Q1 2022-11.9%
Q4 2021+13.7%
Q3 2020+1.5%
Q3 2021+0.2%
Q2 2021-0.1%
Q4 2020+9.5%
Q1 2021+2.3%
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro